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INTRODUCTION
The opening ofa new medical research facility is, by definition, a tangible expression
ofprogress, and a visible demonstration ofcontinuing, firm dedication to medical science.
In this particular instance, celebrating 75 years ofpediatrics atYale, we are afforded a wel-
come opportunity to address a broad question raised often by those whose entire careers
have been devoted to or are likely to be devoted to academic medicine.
The question - what is the world ofmedical science like for those based in the often
frenetic, sometimes tumultuous pharmaceutical industry - can be answered in a number
of ways. The "sound bite" answer is that it is a very different world, ferociously compet-
itive - even dog eat dog (which ofcourse contrasts so sharply with academia where it is
just the opposite). Our less flippant response will focus on the nature and importance of
bridges connecting two of the three key players in our country's medical research enter-
prise: academia and industry. The third key player is, of course, government in its many
forms and functions.
COMPARING AND CONTRASTING RESEARCH
INACADEMIA AND INDUSTRY
To understand more clearly the scientific goals, methods and culture ofthe industrial
side of the medical research bridge, a few vital statistics concerning two organizations,
Yale School of Medicine (YSM)b and Bristol-Myers Squibb (BMS), are illustrative of
today's large academic and large pharmaceutical research organizations. In the most
recent year BMS spent nearly four times as many dollars on research and development
overall as didYSM (Table 1). These dollarvalues are not fully comparable becauseYSM's
number does not include research funds sponsored by clinical departments through their
faculty practices. That degree ofimprecision aside, it is safe to conclude thatYSM and the
BMS Pharmaceutical Research Institute are in thetop tier oftheirrespective kinds ofinsti-
tutions with respect to financial participation in research. Manpower dedicated to the sci-
entific endeavor doesn't differ significantly between the two institutions but the related
expenditures do - reflecting the lower stipends paid to the much larger fraction ofjunior
participants (students; postdoctoral fellows) atYSM.
a To whom all correspondence should be addressed: Dr. Leon E. Rosenberg, Bristol-Myers Squibb
Company, P.O. Box 4000, Princeton, NJ 08543-4000; Tel.: 609-252-4487; Fax: 609 252 6700; E-
mail: rosenbergjleon_e@msmail.bms.com.
bAbbreviations: YSM, Yale University School ofMedicine; BMS, Bristol-Myers Squibb Company.
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Table 1. Vital statistics.
Yale University Bristol-Myers Squibb
School ofMedicine Pharmaceutical Research Institute
1995-1996 1996
Research and Training: $ 215 million Research and Development: $ 800 million
Faculty, Research and Training Staff: 3,000 Scientific and Administrative Staff: 3,600
Major Site: New Haven Four major U.S. sites, linked to a network of
smaller sites worldwide:
Princeton, NJ (Headquarters);
Wallingford, CT; New Brunswick, NJ;
Seattle, WA
Another key difference between these institutions is in single versus multiple research
sites. Conducting all research at a single site providesYSM amajor advantage when com-
pared with the significant obstacles posed by BMS' multiple site network. Foremost
among these obstacles are those pertaining to communication and collaboration - cultur-
al traits thatYSM isjustifiably famous for. Working together over long distances compli-
cates all parts of the research and development organization at BMS. It is particularly
challenging for the Drug Discovery Division, that part of the pharmaceutical research
institute most like the basic science departments in academia, and comprising more than
1000 people and about 75 percent ofthe discovery research budget. This critical group is
spread over three sites (Princeton NJ, Wallingford CT, and Seattle WA). Its internal efforts
are bolstered by three categories ofexternal collaborators: large academic alliances; small
academic collaborations; and various sized relationships with biotechnology companies.
This global array now includes more than 10 academic alliances, 60 smaller targeted tech-
nology and single investigator agreements and 10 highly focused arrangements with
biotechnology companies.
Closer examination of these two representative, leading edge academic and industri-
al institutions suggests research cultures that are distinct, complementary and, sometimes,
convergent. We think there are five important dimensions which must be understood if
alliances between these natural allies are to flourish:
The principal goals are critically different. For academia these are well known: the
acquisition and dissemination of new information; the education ofthe next generation of
medical researchers. Pharmaceutical research and development, on the other hand, has
one overarching goal - the design, discovery, and development of new medicines.
Acquiring proprietary rights through patents and licenses is a secondary, related goal.
Further, dissemination ofknowledge from basic as well as applied science is an important
goal - in common with that of academia.
Theorganizational characters are distinct - as would be expected given the goalsjust
described. The academic setting is noted for the independence and the autonomy of the
individual investigator in initiating research efforts which are highly decentralized and
usually quite discipline oriented. In industry research efforts and priorities are delineated,
not by individual investigator preferences, but rather by a more centralized discovery and
development program aimed at specific disease targets notable for unmet medical need
and commercial opportunity.
The planning modes differ in important ways as well. In academia, research planning
is a responsibility clearly delegated to the principal investigator and episodically tied to
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cycles offunding. In industry, planning is acontinuous undertaking withresponsibility for
strategic program planning seated at thehighest levels oftheresearch organization and fed
from its subunits with their therapeutic area emphasis. The industry planning process is
continuous and inextricably linked to the budget process.
The funding for research programs is similarly distinct. In academia, the sources are
invariably multiple - NIH, NSF, VA, HHMI, foundations, voluntary health agencies. In
industry the source is invariably a single one, the business itself, reflecting the investment
top management considers appropriate given the state ofthe business. In industry, research
funding and business strategy are closely linked. In academia, success in securing fund-
ing defines the scope and scale of the efforts.
Not surprisingly, the principal interactions of academic and industrial medical
research organizations with the federal government differ substantively. The academic
organization has, for many decades, looked beseechingly to a variably responsive govern-
ment for financial sponsorship of its work. In turn, it provides the expertise for the peer
review process that effectively sets the research agenda in the institutions receiving fund-
ing. For the pharmaceutical company's research organization, relationships with the fed-
eral government are primarily and continuously linked to the regulatory oversight func-
tion of the FDA. Our personal experiences tell us that academia's relationship with NIH
and other federal sponsors is more often characterized by advocacy, whereas FDA's rela-
tionship with the pharmaceutical industry is, by its very nature, legalistic and often adver-
sarial. For completeness, it is important to point out industry's involvement with govern-
mentthroughparticipation in cooperative research anddevelopment agreements and in the
peer review process.
While the differences in the two research cultures are real - even formidable - con-
siderable progress has occurred over the last two decades in recognizing their respective
merits and building bridges.
THE BRIDGE BETWEEN ACADEMIA AND INDUSTRY
How are connections to be made between these institutions, so long separated by prej-
udice and misunderstanding as well as by fundamental purpose? To address this, we'll
consider ametaphoric bridge with three structural elements: foundations; forms; and func-
tions
Table 2: Building the bridge between academia and industry.
Key Foundations:
*New biological knowledge and resulting commercial opportunity - the "endless frontier."
*Interdependent Expectations:
- Academia expected to produce research that can be translated into products for
diagnosis and therapy.
- Industry expected to apply new knowledge to product development.
*Interdependent Needs:
-Availability ofcontinuously fresh scientific expertise.
-Durability ofRelationships:
- Openness ofcommunication
- Respect for proprietarty concerns
-Agreed upon ownership of intellectual property rights
- Funding to fuel the effort
- Due dillegence in commercializing inventions
- Sharing the rewards of success
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Table 2 suggests the key elements of the foundation that are necessary for a bridge
between the two cultures - elements which permit the structure to be built and to endure.
The sharing of an "endless frontier" view of science (as described by Vannevar Bush) is
the most basic ingredient. This element cannot suffice in the absence ofacknowledgment
by the parties involved that their expectations and needs are and must remain interdepen-
dent throughout a relationship whether short-term and highly focused or longer term and
ofbroader scope. The durability ofan effective bridge must be continuously tested against
the openness ofcommunication achieved, against the need to respectproprietary concerns
of the industrial party, against the agreements reached concerning ownership of intellec-
tual property and those articulating the flow of funds for the effort. Ultimately, for the
bridge to remain viable, there must be inventions to commercialize and rewards to be
shared therefrom.
The characteristic forms of the bridge follow from the foundation "stones" just
described. The most common, and some would say the most successful, form is repre-
sented by an industrial research contract with an individual academic investigator. These
are aimed at focused acquisition of targets or technologies. Closely allied are the some-
what more broad-based agreements with one or a group of academic investigators aimed
at a single therapeutic area. Quite straightforward arrangements govern industry's pur-
chase ofexclusive and non-exclusive technology licenses with varying royalty provisions
and the traditional employment of academic consultants who serve on a retainer basis.
Less frequent, and to date less successful in meeting the interdependent expectations and
needs ofthe parties, have been the large "umbrella" agreements with an academic institu-
tion covering multiple investigators and/or targets. Historically general in scope, such
agreements are often: less easily understood by the working scientists in the participating
organizations; more difficult to oversee; and seen as too unrestricted to provide value to
the industrial partner.
Figure 1: Academia/Industry Cooperation.
Academia/industry Cooperation
,>
* Yale/D4T/BMS benefiting
each other
* Yale/D4T/BMS benefiting
patients with a widely
approved therapy for adults
and children: Zerite - 1996
* 1996 and beyond: expansion
potential In combination with
other agents
Yale
* Antiviral Research
* Expertise in Infectious
disease chemistry
* Discovers D4T, an
antiviral nucleoside
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agreement - 1982-1995
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* Licenses patents to
BMS -1988
BMS
* Antiviral Research and
Development expertise
* Licenses the D4T patents
for R&D in 1988
* Develops and secures an
approved NCE
* Zerlte-1993-1995
U.S., U.K., France,
Germany, Italy, Spain;
1996 - U.S. approval for
treating children
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The third structural element of our metaphoric bridge pertains to the key functions
that the bridge subtends. In our view the following four key functions are essential:
*To emphasize continuously that improving the health of the public is the overarch-
ing goal ofthe country's medical research enterprise;
*To bring to the public the specific "fruits" of the nation's investment in medical
research by accelerating progress in identifying and developing solutions to important
medical problems;
*To replenish society's intellectual capital, i.e. the human pipeline, of the medical
research enterprise;
*To permit academic investigators and institutions to share equitably in the financial
rewards oftheir discoveries.
YALE AND BMS: A CONTEMPORARY EXAMPLE
From the numerous academic/industrial collaborations the authors have worked with,
and from review ofthe considerable literature available concerning specific arrangements,
one bridge involving YSM and BMS is a shining success. Figure 1 depicts this particular
"span." Building on successful negotiation, this cooperation focused squarely on the com-
mon goal of improving health, in this instance improving antiviral therapy for patients
with HIV. It recognized the differences between the partners and maximized their respec-
tive contributions. At one end, YSM contributed its expertise in antiviral and infectious
disease research; at the other end, BMS provided its antiviral research and development
expertise. Linked by patents and license agreements, the industrial partner developed and
secured broad geographic approval for a new HIV reverse transcriptase inhibitor effective
in adults and children - d4T (Zerit). This medication is being widely used as part of the
two and three drug combinations that are changing the outlook for patients with AIDS.
It took more than 15 years for YSM and BMS to build, travel, and maintain this
bridge. It involved risk, uncertainty, debate, patience and trust. This particular bridge epit-
omizes the best in American medical research - creative basic science, effective tech-
nology transfer, committed industrial capability. More than a dream, successful academ-
ic/industrial cooperation may truly be the next critical frontier for our country's and the
world's medical research enterprises.
CONCLUSION
As the Yale Children's Hospital Research Center opens, we see a strong parallel for
it and the metaphoric bridge we have been discussing. The new Center is ajewel inYale's
crown; a site where intellectual strength and fine facilities meld to support one of acade-
mia's premier departments of Pediatrics. The Center will be a home for the discovery of
fundamental knowledge which, hopefully will bridge, with industry's participation, to pre-
ventive, diagnostic or therapeutic modalities aimed toward improving the present and
future health of our country's most precious resource - its children.
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